Screener
ADMA Biologics ADMA Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: ADMA Biologics’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 5:16 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001140361-26-019336
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Purchase of property and equipment | (2,543) | (4,701) |
| Acquisition of intangible assets | (53) | (19) |
| Proceeds on the sales of assets held for sale | 5,000 | - |
| Net cash provided by (used in) investing activities | 2,404 | (4,720) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| JPM term loan payments | (469) | - |
| JPM revolving facility proceeds | 125,000 | - |
| Taxes paid on vested restricted stock units | (5,058) | (7,228) |
Item 1.
FAQ
- What is ADMA Biologics's investing cash flow?
- ADMA Biologics (ADMA) reported investing cash flow of $2.4M in Q1 2026.
- How has ADMA Biologics's investing cash flow changed year-over-year?
- ADMA Biologics's investing cash flow increased by 150.9% year-over-year, from -$4.72M to $2.4M.
- What is the long-term trend for ADMA Biologics's investing cash flow?
- Over 4 years (2021 to 2025), ADMA Biologics's investing cash flow has grown at a 12.8% compound annual growth rate (CAGR), from -$13.51M to -$21.89M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about ADMA Biologics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude